Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Cameron Santoro is an associate editor for The Center for Biosimilars

Articles

Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions.

Biosimilar Approval and Uptake Impacted by Global Regulatory Frameworks

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in advanced non–small cell lung cancer (NSCLC)

Retrospective Study Shows Bevacizumab Biosimilar Efficacy in NSCLC

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.

Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.

Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone

About

Editorial

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

This new eBook from The Center for Biosimilars

® tells the compelling story of how biosimilar development and uptake have been affected by COVID-19. Read it and find out how biosimilars may emerge from the pandemic as a more powerful, more valuable force in lower-cost medicine.

The Disruptor: How Coronavirus Disease 2019 (COVID-19) Has Affected the Development and Uptake of Biosimilars

Are you ready for the upcoming 2020 transition of insulins and other therapeutic proteins to US regulation as biologics and biosimilars? Find out what you need to know about the regulatory change with a new ebook from The Center for Biosimilars®.

Preparing for the 2020 Regulatory Transition of Insulin and Other Therapeutic Proteins

Strategies for Successful Adoption of Biosimilars in Practice: Takeaways From the West Cancer Center Experience

Biosimilars 101:  Practice Concerns, Market Acceptance, and the Biosimilars Pipeline

Pfizer Global Biosimilars Commercial Lead, Roman Irsiegler, gives his thoughts on why a sustainable biosimilars market is critical for the healthcare industry, and what stakeholders can do to achieve it.

How can we achieve a long-term sustainable biosimilars market?

What is key to achieving a long-term sustainable biosimilars market?

Resources

Strategies for Successful Adoption of Biosimilars in Practice: Takeaways From the West Cancer Center Experience

Date:

Biosimilars 101: Practice Concerns, Market Acceptance, and the Biosimilars Pipeline

Date:

How can we achieve a long-term sustainable biosimilars market?

Date:

What is key to achieving a long-term sustainable biosimilars market?

Date: